National Cancer Centre Singapore shared a post on LinkedIn:
“Congrats to Associate Professor Choon Kiat Ong and the NCCS Lymphoma Translational Research Laboratory team on their groundbreaking research published in Cancer Discovery!
The novel combo therapy studied offers new hope for patients with relapsed/refractory natural killer/T-cell lymphoma (R/R NKTL) – a rare and aggressive cancer with limited treatment options. By combining epigenetic therapy with an anti-PD-1 antibody, ‘cold’ tumours became ‘hot’ and were resensitised to treatment, significantly improving patient outcomes.
This important work, conducted in collaboration with Sun Yat-sen University Cancer Center, has been selected for press release by the prestigious American Association for Cancer Research (AACR) – a testament to its significance. Read more about this exciting work here.”
More posts featuring the National Cancer Centre Singapore.